Drug
IDE397
IDE397 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Active, not recruiting1
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
active_not_recruiting133%
completed133%
recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
completedphase_1
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
NCT05975073
active_not_recruitingphase_1
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
NCT04794699
recruitingphase_1
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT07277413
Clinical Trials (3)
Showing 3 of 3 trials
NCT05975073Phase 1
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
NCT04794699Phase 1
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
NCT07277413Phase 1
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3